2142
C. D. Anderson et al.
LETTER
(6) (a) Hewlett, N. M.; Tepe, J. J. Org. Lett. 2011, 13, 2011.
(b) Jung, S. H.; Kohn, H. J. Am. Chem. Soc. 1985, 107, 2931.
(7) Hassner, A.; Lorber, M. E.; Heathcock, C. J. Org. Chem.
1967, 32, 540.
O
O
R1
C
C
I
AgOCN
I2
N
N
I
+
R1
R1
n
(8) (a) Chiang C. G., Stevenson T. M., Thieu T. V., Gebreysus
C., Yatsko C.; 219th National ACS Meeting Poster No.
ORGN 615, March 28th, 2000. (b) Huang, H.; La, D. S.;
Cheng, A. C.; Whittington, D. A.; Patel, V. F.; Chen, K.;
Dineen, T. A.; Epstein, O.; Graceffa, R.; Hickman, D.;
Kiang, Y. H.; Louie, S.; Luo, Y.; Wahl, R. C.; Wen, P. H.;
Wood, S.; Fremeau, R. T. Jr. J. Med. Chem. 2012, 55, 9156.
(9) (a) Pitha, J.; Jonas, J.; Kovar, J.; Blaha, K. Collect. Czech.
Chem. Commun. 1961, 26, 834. (b) Garcia Fernandez, J. M.;
Ortiz Mellet, C.; Pradera Adrian, M. A.; Fuentes Mota, J.
J. Heterocycl. Chem. 1991, 28, 777. (c) Cordi, A. A.;
Lacoste, J.-M.; Descombes, J.-J.; Courchay, C.; Vanhoutte,
P. M.; Laubie, M.; Verbeuren, T. J. J. Med. Chem. 1995, 38,
4056. (d) Tiecco, M.; Testaferri, L.; Marini, F.; Temperini,
A.; Bagnoli, L.; Santi, C. Synth. Commun. 1997, 27, 4131.
(10) Hassner, A. In Encyclopedia of Reagents for Organic
Synthesis; Paquette, L., Ed.; John Wiley & Sons: New York,
1995, 2808.
4
n
n
5
6
R2R3NH
DIPEA
R2
R3
N
O
O
R2
N
HN
N
+
R3
R1
R1
n
n
7
8
examples (isolated yield)
N
N
O
N
(11) (a) Zeng, L.; Kassel, D. B. Anal. Chem. 1998, 70, 4380.
(b) Zeng, L.; Wang, X.; Wang, T.; Kassel, D. B. Comb.
Chem. High Throughput Screening 1998, 1, 101. (c) Zeng,
L.; Burton, L.; Yung, K.; Shushan, B.; Kassel, D. B. J.
Chromatogr., A 1998, 794, 3.
N
N
N
O
O
7a
(28%)
7b
7c
(12) Hassner, A.; Lorber, M. E.; Heathcock, C. J. Org. Chem.
1967, 32, 540.
(19%)
(15%)
(13) Of the 575 reactions, 311 of the products were recovered in
milligram quantities and >85% pure (by LC/MS) after
HPLC purification.
Scheme 2 Synthesis of spirocyclic 2-aminooxazolidines
(14) Synthesis of 5-[4-(tert-butoxy)phenyl]-N,N-di-n-propyl-
4,5-dihydrooxazol-2-amine (Table 1, entry 8); Typical
Procedure: To a solution of iodine (38 mg, 0.15 mmol) in
THF (0.3 mL) in an amber vial (wrapped in foil to exclude
light), was added silver cyanate (29 mg, 0.195 mmol) and the
mixture was stirred vigorously under subdued light for
30 min. 4-tert-Butoxystyrene (0.028 mL, 0.15 mmol) in
THF (0.1 mL) was added and the reaction mixture was
stirred vigorously for 16 h at room temperature under
subdued light. The suspension was filtered through a
0.45 μm filter, under subdued light, to remove silver salts.
Di-n-propylamine (0.021 mL, 0.15 mmol) and DIPEA (0.05
mL, 0.3 mmol) in THF (0.1 mL) were added to the INCO
intermediate and the reaction mixture was stirred for 16 h at
room temperature. Evaporation of the reaction mixture
followed by HPLC purification gave the title compound as a
red oil. Yield: 18 mg (40%). 1H NMR (400 MHz, CDCl3): δ
= 7.18 (d, J = 8.6 Hz, 2 H), 6.95 (d, J = 8.5 Hz, 2 H), 5.11–
5.02 (m, 1 H), 4.58 (t, J = 8.5 Hz, 1 H), 4.01 (t, J = 7.3 Hz,
1 H), 3.43–3.16 (m, 4 H), 1.80–1.64 (m, 4 H), 1.34 (s, 9 H),
0.94 (t, J = 7.4 Hz, 6 H). 13C NMR (101 MHz, CDCl3): δ =
162.48, 154.36, 126.92, 124.30, 78.22, 77.22, 75.47, 67.42,
50.04, 28.82, 21.44, 11.23. IR (neat): 1647, 1504, 1233,
1158, 895 cm–1. LC/MS (ESI): tR = 1.36 min (XIC
maximum, 3 min run; m/z [M + H]+ found: 319.3). HRMS
(ESI): m/z [MH]+ calcd for C19H31N2O2: 319.2386; found:
319.2393.
allel synthesis and automation, making it useful for the
preparation of 2-aminooxazolines libraries.
Acknowledgment
We thank George Trainor, Mark Suto, Peter Myers, and Robyn
Rourick for their support, technical assistance, and helpful discus-
sions.
References
(1) Current addresses: (a) Bristol-Myers Squibb Pharma
Research Labs, 4570 Executive Drive, Suite 400, San Diego,
CA 92121, USA. (b) Theravance Inc., 901 Gateway Blvd.,
South San Francisco, CA 94080, USA. (c) Genomics
Institute of the Novartis Research Foundation, 10675 John
Jay Hopkins Dr., San Diego, CA 92121, USA.
(2) (a) Poos, G. I.; Carson, J. R.; Rosenau, J. D.; Roszkowski, A.
P.; Kelley, N. M.; McGowin, J. J. Med. Chem. 1963, 6, 266.
(b) Harnden, M. R.; Rasmussen, R. J. Med. Chem. 1970, 13,
305. (c) Freiter, E. R.; Abdallah, A. H.; Strycker, S. J.
J. Med. Chem. 1973, 16, 510.
(3) Hong, S.-S.; Bavadekar, S. A.; Lee, S.-I.; Patil, P. N.;
Lalchandani, S. G.; Feller, D. R.; Miller, D. D. Bioorg. Med.
Chem. Lett. 2005, 15, 4691.
(4) Wong, W. C.; Sun, W.; Cui, W.; Chen, Y.; Forray, C.;
Vaysse, P. J.-J.; Branchek, T. A.; Gluchowski, C. J. Med.
Chem. 2000, 43, 1699.
(15) Prior work (see ref. 8a) had suggested that exocyclic
methylidene reactants did not produce the desired 2-
aminooxazolines, instead, giving the corresponding allylic
iodide through simple addition/elimination.
(5) Touzeau, F.; Arrault, A.; Guillaumet, G.; Scalbert, E.;
Pfeiffer, B.; Rettori, M.; Renard, P.; Mércour, J. J. Med.
Chem. 2003, 46, 1962.
Synlett 2013, 24, 2140–2142
© Georg Thieme Verlag Stuttgart · New York